An In-depth Exploration of Contemporary Approaches in the Management of Enteric Fever for Healthcare Professionals
OthersPage Navigation
Introduction
Enteric fever, predominantly caused by Salmonella Typhi and Paratyphi, remains a significant health challenge.
Modern Therapeutic Strategies
Contemporary management includes antibiotic therapy, with third-generation cephalosporins and fluoroquinolones as first-line treatments. However, antibiotic resistance necessitates newer approaches.
Preventive Measures
Vaccination and improved sanitation play vital roles in prevention. Typhoid conjugate vaccines (TCVs) have shown promising results.
Conclusion
While antibiotics remain essential, evolving resistance underscores the need for novel strategies in managing enteric fever, emphasizing the importance of preventive measures.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
2.
New drug combination shows particularly good results in patients with HPV-negative head and neck cancer
3.
Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL
4.
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll
5.
In a clinical trial, "3D mammography" nearly reduces the incidence of breast cancer between two screening exams.
1.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
2.
Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research
3.
Unlocking the Mystery of Basilar Artery Stroke: A New Approach to Treatment
4.
Quality of Life Optimization in Long-Term Cancer Survivorship
5.
Molecular Matching for Individualized Blood-Disorder Therapy
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
5.
How Nutrition Can Support Patients During Cancer Care
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge